Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. (GILD) and partner Merck (MRK) announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed a treatment switch to an investigational oral once-weekly combination regimen of islatravir and lenacapavir maintained viral suppression in adults at week 48.Shares of the company have risen 6.2% year to date against the industry’s decline of 1.7%.Image Source: Zacks Investment ResearchData From GILD an ...